|
March 16, 2006 Categories: Uncategorized Posted by admin
Guidant Corporation (NYSE: GDT) March, 9 announced enrollment of the first patient in a first-in-man clinical trial designed to evaluate the safety of a fully bioabsorbable everolimus eluting stent platform for the treatment of coronary artery disease. The trial, called ABSORB, will enroll up to 60 patients in Belgium, Denmark, France, New Zealand, Poland and The Netherlands.
Full news
|
|
